Details for New Drug Application (NDA): 090092
✉ Email this page to a colleague
NDA 090092 describes ZIDOVUDINE, which is a drug marketed by Aurobindo Pharma Ltd, Cipla Ltd, Am Regent, Liaoning Chengda, Aurobindo, Aurobindo Pharma, Cipla, Hec Pharm, Hetero Labs Ltd Iii, Hikma, Norvium Bioscience, and Ranbaxy Labs Ltd, and is included in fifteen NDAs. It is available from two suppliers. Additional details are available on the ZIDOVUDINE profile page.
The generic ingredient in ZIDOVUDINE is zidovudine. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the zidovudine profile page.
The generic ingredient in ZIDOVUDINE is zidovudine. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the zidovudine profile page.
Summary for 090092
| Tradename: | ZIDOVUDINE |
| Applicant: | Hetero Labs Ltd Iii |
| Ingredient: | zidovudine |
| Patents: | 0 |
Pharmacology for NDA: 090092
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 090092
Suppliers and Packaging for NDA: 090092
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZIDOVUDINE | zidovudine | TABLET;ORAL | 090092 | ANDA | Camber Pharmaceuticals, Inc. | 31722-509 | 31722-509-60 | 12 BOTTLE in 1 CASE (31722-509-60) / 60 TABLET in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Apr 25, 2008 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
